GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Theriva Biologics Inc.
Theriva Biologics is a biotech company developing oncolytic viruses capable of disrupting tumor barriers. Its stock price represents a venture bet on an innovative approach to immunotherapy, with the company's value entirely dependent on the clinical success of its lead drug, VCN-01, in treating difficult-to-treat cancers such as pancreatic cancer.
Share prices of companies in the market segment - Oncology immuno-therapy
Theriva Biologics is an oncology company developing drugs that use viruses to infect and destroy cancer cells and stimulate the immune system. We've categorized it as an "Immuno-Oncology" company. The chart below shows the dynamics of the oncolytic virotherapy sector.
Broad Market Index - GURU.Markets
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other cancer treatments. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TOVX - Daily change in the company's share price Theriva Biologics Inc.
For Theriva Biologics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Theriva Biologics develops oncolytic viruses and other drugs to stimulate the immune system against cancer. Immuno-oncology is a highly volatile sector. The chart below shows the average fluctuations in this industry, providing context for assessing the risks and potential of TOVX shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Theriva Biologics is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Theriva Biologics Inc.
Theriva Biologics, Inc.'s year-to-date performance tells the story of its diversified approach to cancer treatment. Its trailing-12-month market cap reflects progress in its programs, including oncolytic viruses and drugs to prevent chemotherapy side effects. Success in any of these areas could significantly boost its valuation.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Theriva, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news of clinical trials of its oncolytic virotherapy. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Theriva Biologics is an immuno-oncology company whose stock is a bet on a new generation of cancer drugs. Its performance is completely disconnected from the market and is determined by news of the clinical successes or failures of its virus therapy. It's a high-risk play where scientific data is everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Theriva Biologics Inc.
Theriva is a clinical-stage immuno-oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its oncolytic viruses and other programs prompts an immediate investor reaction.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Oncolytic viruses are a cutting-edge approach in immuno-oncology, where viruses are used to fight cancer. The dynamics of this biotech sector, shown in the graph, reflect its high research intensity and risks. One company operating in this field is Theriva Biologics.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Theriva Biologics is a clinical-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on research data, paying little attention to overall market trends. The chart illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Theriva Biologics Inc.
Theriva Biologics, a company developing oncolytic viruses and other immunotherapeutic approaches, is at the forefront of the fight against cancer. Its weekly stock price is reflecting clinical trial data that may confirm the potential of its platform for treating difficult-to-treat tumors.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Theriva Biologics develops oncolytic viruses and other drugs to stimulate the immune system against cancer. This is a promising area of immuno-oncology. This chart allows us to separate the impact of news specific to Theriva from general trends observed in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Theriva Biologics develops oncolytic viruses, a promising area of immuno-oncology. This chart allows us to separate the impact of Theriva-specific news from general market trends.
Market capitalization of the company, segment and market as a whole
TOVX - Market capitalization of the company Theriva Biologics Inc.
Theriva Biologics' market capitalization reflects investor bets on its oncolytic viruses and drugs that protect against chemotherapy side effects. The chart demonstrates the market's faith in its dual approach to cancer treatment. Its low valuation reflects the high risk associated with developing anti-cancer drugs and the long road to approval.
TOVX - Share of the company's market capitalization Theriva Biologics Inc. within the market segment - Oncology immuno-therapy
Theriva Biologics develops oncolytic viruses and other immunotherapies for cancer treatment. Its market share is small, but it has a promising approach. The company is betting on its platform, which uses viruses to infect and destroy tumor cells.
Market capitalization of the market segment - Oncology immuno-therapy
Below is a chart showing the total value of the entire biotech sector specializing in immuno-oncology. For Theriva, which operates in this field, this line represents the future of cancer treatment. The chart's rise reflects investors' belief that new approaches using viruses and the immune system can defeat even the most resistant tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
Theriva Biologics develops oncolytic viruses and other drugs to stimulate the immune system against cancer. Its capitalization is based on the evaluation of a combination approach in immuno-oncology.
Book value capitalization of the company, segment and market as a whole
TOVX - Book value capitalization of the company Theriva Biologics Inc.
Theriva Biologics develops oncolytic viruses for cancer treatment. Its book value is its scientific and financial capital. It consists of cash flow for clinical trials and the value of its viral platforms. How has this innovation capital changed? The chart below shows.
TOVX - Share of the company's book capitalization Theriva Biologics Inc. within the market segment - Oncology immuno-therapy
Theriva Biologics, Inc. is an oncology company developing oncolytic viruses. Its unique approach requires sophisticated infrastructure: in-house or contracted GMP facilities for the production of its viral drugs. The chart shows the company's share of the physical infrastructure required for this line of immunotherapy.
Market segment balance sheet capitalization - Oncology immuno-therapy
Theriva Biologics is an oncology company. The pharmaceutical industry, as the graph shows, is both knowledge- and capital-intensive. Theriva focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Theriva Biologics' assets are not factories, but a portfolio of developments in oncolytic viruses and other immunotherapeutic approaches to fighting cancer. The book value reflects the capital invested in clinical trials of these innovative treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Theriva Biologics Inc.
Theriva Biologics is an oncology company developing virus-based drugs to fight cancer. Its market value is determined by the valuation of its scientific platform. Investors are betting on its potential to turn viruses into allies in the fight against cancer.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Theriva Biologics is a biotech company developing oncolytic viruses to fight cancer. Its high valuation on this chart reflects investors' faith in this cutting-edge treatment that uses viruses to destroy tumors.
Market to book capitalization ratio for the market as a whole
Theriva Biologics uses viruses to fight cancer, a cutting-edge approach in immuno-oncology. The company's market value reflects investors' faith in the potential of this technology. This chart demonstrates the market's willingness to invest in risky but potentially revolutionary treatments.
Debts of the company, segment and market as a whole
TOVX - Company debts Theriva Biologics Inc.
Theriva, a biopharmaceutical company developing oncolytic viruses, is funding its clinical trials with raised capital. This chart illustrates the high risk and cost of developing an innovative, but not yet widely proven, cancer therapy.
Market segment debts - Oncology immuno-therapy
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other immunotherapeutic approaches for cancer treatment. This chart shows how the company funds its clinical-stage research in one of the most advanced areas of oncology, which requires significant capital and carries high risks.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Theriva Biologics Inc.
Theriva Biologics develops oncolytic viruses and other immunotherapeutic drugs for cancer treatment. This is one of the most advanced and capital-intensive areas in oncology. This chart shows how heavily the company relies on debt to finance its expensive and high-risk clinical trials.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Theriva Biologics develops oncolytic viruses and other cancer treatments. Immuno-oncology is one of the most expensive areas in pharmaceuticals. This chart shows how the company finances its clinical trials. It relates its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
Theriva Biologics develops oncolytic viruses and other cancer treatments. Immuno-oncology is one of the most capital-intensive areas in biotech. How heavily does the company rely on debt financing for its breakthrough research? This graph of total debt in the economy helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Theriva Biologics Inc.
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other immunotherapeutic drugs for the treatment of cancer. This chart shows how investors value its pipeline. The valuation is volatile and depends on clinical trial results.
P/E of the market segment - Oncology immuno-therapy
Theriva Biologics is an oncology company developing oncolytic viruses and other immunotherapeutic approaches for cancer treatment. This chart illustrates the average valuation in the immuno-oncology sector, where investors are betting on breakthrough but high-risk approaches to cancer treatment.
P/E of the market as a whole
Theriva Biologics, Inc. is a biopharmaceutical company developing oncolytic viruses and other immunotherapeutic drugs for the treatment of cancer. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether TOVX's high valuation is based on faith in its scientific platform or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Theriva Biologics Inc.
Theriva Biologics, formerly Orgenesis, is an oncology company developing oncolytic viruses and other immunotherapeutic approaches for cancer treatment. This chart shows how investors view the scientific potential and commercial prospects of its promising immunotherapy developments.
%20P%2FE%20Theriva%20Biologics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Theriva-Biologics-Inc.&v=1772689580819 "Chart of the company's future (projected) P/E Theriva Biologics Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Theriva Biologics develops oncolytic viruses and other immunotherapeutic drugs for cancer treatment. The chart shows average profitability expectations for the sector, helping to understand the level of investor confidence in its scientific developments in one of the most promising areas of modern oncology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772689580820 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Theriva Biologics develops oncolytic viruses and other immunotherapeutic drugs for cancer treatment. It is at the forefront of the fight against cancer. This biotech risk appetite chart shows how willing investors are to finance complex and high-risk approaches in immuno-oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772689580823 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Theriva Biologics Inc.
Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company developing oncolytic viruses and other immunotherapeutic agents for the treatment of cancer. Financial metrics reflect R&D expenditures. This chart shows investments in cutting-edge methods that utilize viruses and the immune system to fight tumors.
Profit of companies in the market segment - Oncology immuno-therapy
Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company developing oncolytic viruses and other immunotherapeutic agents for the treatment of cancer. This chart shows the overall profitability of the immuno-oncology sector, one of the fastest-growing and most innovative in modern pharmaceuticals.
Overall market profit
Theriva Biologics, Inc. is a biopharmaceutical company developing oncolytic viruses to combat cancer. The company is at the forefront of innovation. Its future depends solely on the success of clinical trials. The overall economic environment, as shown in this chart, does not impact the need for new cancer treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Theriva Biologics Inc.
Theriva Biologics develops oncolytic viruses and other immunotherapies to combat cancer. Future profits depend on the success of its drugs in clinical trials, both as monotherapies and in combination. This chart reflects analysts' speculative expectations for its oncology portfolio.
%20profit%20of%20the%20company%20Theriva%20Biologics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Theriva-Biologics-Inc.&v=1772689580839 "Graph of future (projected) profit of the company Theriva Biologics Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Theriva Biologics (formerly Orgenesis) is an oncology company developing drugs based on oncolytic viruses and immunomodulators for the treatment of cancer. Its approach involves combining various methods to attack tumors. This chart shows revenue projections for the immuno-oncology sector, providing context for assessing Theriva's strategy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772689580850 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Theriva Biologics, Inc. is a biopharmaceutical company developing oncolytic viruses for the treatment of cancer. Its future depends on the success of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772689580859 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Theriva Biologics Inc.
Theriva Biologics develops oncolytic viruses and other immunotherapeutic drugs to fight cancer. Revenue is minimal at the clinical stage. This chart reflects investors' assessment of its scientific pipeline and their belief that its drugs will be part of the future of combination cancer treatments.
P/S market segment - Oncology immuno-therapy
Theriva Biologics is a late-stage biopharmaceutical company developing oncolytic viruses and other immunotherapeutics for the treatment of cancer. Their approach focuses on using viruses to destroy tumors and stimulate anti-cancer immunity. This chart reflects the average revenue estimate for the sector, which helps assess the potential of this platform.
P/S of the market as a whole
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other immunotherapeutic drugs for the treatment of cancer. This chart highlights that the valuation of such companies is based on the potential of their platforms to combat oncology diseases, which contrasts sharply with the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Theriva Biologics Inc.
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other cancer treatments. The company's future revenue valuation is critical for a clinical-stage company. It reflects investors' confidence in the potential of its platform to develop new treatments that can work in combination with existing therapies to combat aggressive tumors.
%20P%2FS%20Theriva%20Biologics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Theriva-Biologics-Inc.&v=1772689580879 "The graph of the company's future (projected) P/S Theriva Biologics Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other immunotherapeutic drugs for the treatment of cancer. This chart compares the company's estimated future sales with expectations for the oncology sector. It shows how investors view the potential of its viral therapy to stimulate the immune system against tumors.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772689580884 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Theriva Biologics develops oncolytic viruses and other immunotherapeutic agents for the treatment of cancer. The company's future depends on the success of its combination approaches in clinical trials. This chart of overall market expectations reflects investor belief that synergy between various immunotherapies is key to defeating cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772689580885 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Theriva Biologics Inc.
This figure reflects the financial activity of Theriva Biologics, a biopharmaceutical company developing oncolytic viruses and other immunotherapeutic approaches for cancer treatment. Being in clinical trials, the company does not have stable sales revenue.
Sales of companies in the market segment - Oncology immuno-therapy
Theriva Biologics (formerly Orgenesis) is focused on developing oncolytic viruses and other cancer treatments. Being in the clinical stage, it does not yet have sales revenue. Its future revenue will depend on the success of its candidates, which target some of the most difficult-to-treat cancers, such as pancreatic cancer.
Overall market sales
Theriva Biologics, Inc. develops oncolytic viruses and other immunotherapeutic agents for the treatment of cancer. The company is at the forefront of the fight against cancer. This general economic chart bears no relation to Theriva's prospects, which are determined solely by scientific breakthroughs and clinical trial successes.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Theriva Biologics Inc.
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other immunotherapeutic drugs for the treatment of cancer. Future revenues are dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its portfolio of anticancer drugs that stimulate the immune system to fight tumors.
%20sales%20of%20the%20company%20Theriva%20Biologics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Theriva-Biologics-Inc.&v=1772689580892 "Schedule of future (projected) sales of the company Theriva Biologics Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Theriva Biologics develops oncolytic viruses and other immunotherapies to fight cancer. This chart shows the forecast for the oncology sector. Is market growth expected thanks to new approaches that "teach" the immune system to attack cancer? This reflects the overall potential of this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772689580895 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Theriva Biologics is a biopharmaceutical company developing oncolytic viruses and other drugs for the treatment of cancer. Its success depends on the results of clinical trials and combinations with other therapies. This schedule does not affect the need of cancer patients for innovative and more effective treatments, which is the primary driver of its business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772689580898 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Theriva Biologics Inc.
Theriva Biologics (formerly Orgenesis) develops oncolytic viruses and other immunotherapeutic agents for the treatment of cancer. This chart reflects its financial performance at the clinical trial stage. Profitability is a future goal and will depend on the success of its candidates in demonstrating their ability to effectively combat tumors, particularly pancreatic cancer.
Market segment marginality - Oncology immuno-therapy
Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company developing oncolytic viruses and other immunotherapeutic agents for the treatment of cancer. This chart reflects its financial position, where profitability depends on the success of its candidates in clinical trials, both independently and in combination with other treatments.
Market marginality as a whole
Theriva Biologics develops oncolytic viruses and other cancer immunotherapy drugs. The company is at the forefront of the fight against cancer. This gross profitability chart reflects the investment climate and the market's willingness to fund high-risk but potentially breakthrough approaches to cancer treatment.
Employees in the company, segment and market as a whole
Number of employees in the company Theriva Biologics Inc.
Theriva Biologics (formerly Orgenesis) develops oncolytic viruses and other cancer treatments. Its small staff of scientists and clinicians is its greatest asset. This chart shows how the biotech company manages its resources during clinical trials, where even a small increase in the team can mean progress in key programs.
Share of the company's employees Theriva Biologics Inc. within the market segment - Oncology immuno-therapy
Theriva Biologics is an oncology company developing drugs based on oncolytic viruses and other approaches to stimulating the immune system against cancer. Its R&D program requires a team of virologists and immunologists. This graph shows the company's share of the biotech labor market, reflecting the scale of its research in the cutting-edge field of immuno-oncology.
Number of employees in the market segment - Oncology immuno-therapy
Theriva Biologics develops oncolytic viruses and other immunotherapeutic drugs for the treatment of cancer. The chart illustrates its activities in the immuno-oncology sector. The company uses modified viruses that selectively infect and destroy cancer cells, while simultaneously stimulating an immune response against the tumor.
Number of employees in the market as a whole
Theriva Biologics develops oncolytic viruses and other drugs for cancer immunotherapy. It is at the cutting edge of medicine, and the company's growth is driven by scientific advances. Against the backdrop of the overall job market picture shown in this chart, Theriva represents the world of biotech, where jobs are being created to revolutionize cancer treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Theriva Biologics Inc. (TOVX)
Theriva Biologics is a biotech company developing oncolytic viruses (cancer-killing viruses) for the treatment of cancer. This is cutting-edge R&D. This chart shows the speculative value the market places on their pipeline (for example, VCN-01). It reflects the market capitalization per scientist.
%20of%20the%20company%20Theriva%20Biologics%20Inc.%20(TOVX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Theriva-Biologics-Inc.-TOVX&v=1772689580923 "Chart of market capitalization per employee (in thousands of dollars) of the company Theriva Biologics Inc. (TOVX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Theriva Biologics (TOVX) develops oncolytic viruses and other immunotherapeutics for cancer treatment. In this cutting-edge field of oncology, this chart represents the value of their scientific platform. The high market capitalization per employee may indicate that investors see potential in their combined approach to overcoming tumor resistance.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772689580942 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Theriva Biologics is an oncology company developing drugs based on oncolytic viruses. The company's value lies in its scientific platform. The graph shows a high employee valuation, as the market sees potential in using viruses to selectively kill cancer cells, a promising area of immunotherapy.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772689580946 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Theriva Biologics Inc. (TOVX)
Theriva Biologics is a clinical-stage biotech company developing oncolytic viruses and other cancer treatments. This chart shows the net loss per employee, reflecting the fact that every scientist at the company represents an R&D investment, funded for expensive clinical trials.
%20Chart%20Theriva%20Biologics%20Inc.%20(TOVX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Theriva-Biologics-Inc.-TOVX&v=1772689580949 "Company Profit Per Employee (in thousands of dollars) Chart Theriva Biologics Inc. (TOVX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Theriva Biologics, Inc. is a biopharmaceutical company developing oncolytic viruses and other cancer treatments. In immuno-oncology, productivity per employee reflects progress in clinical trials. This graph shows the financial return per team, allowing one to assess the company's stage of development and the potential of their platform.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772689580990 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Theriva Biologics is a biotech company focused on oncology. They use oncolytic viruses and other platforms to fight cancer. It's an R&D business. This chart, showing average market efficiency, helps clarify the contrast with biotech, where teams of scientists burn through capital in hopes of a breakthrough.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772689580997 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Theriva Biologics Inc. (TOVX)
Theriva Biologics is an oncology company developing drugs based on oncolytic viruses. At the clinical stage, revenue per employee can be zero. The graph represents future potential: a successful therapy could become a breakthrough in cancer treatment and generate astronomical revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Theriva-Biologics-Inc.-TOVX&v=1772689581009 "Sales chart per company employee Theriva Biologics Inc. (TOVX)")
Sales per employee in the market segment - Oncology immuno-therapy
Theriva Biologics (TOVX) is a clinical-stage biotech developing oncolytic viruses (for fighting cancer) and gastrointestinal protective drugs for chemotherapy. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of Theriva's R&D staffing efficiency.
Sales per employee for the market as a whole
Theriva Biologics (TOVX) is a biotech company developing oncolytic viruses (for fighting cancer) and other drugs. Currently, their business is focused on R&D. This chart reflects their clinical stage: the company invests in research and has no commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Theriva Biologics Inc. (TOVX)
Theriva (TOVX) is a biotech company developing oncolytic (cancer-killing) viruses. This chart tracks short positions. Short positions reflect the high risk of this technology and a bet that the company's trials (like those of Calidi and CLDI) will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Theriva-Biologics-Inc.-TOVX&v=1772689581042 "Short Shares Chart for the Company Theriva Biologics Inc. (TOVX)")
Shares shorted by market segment - Oncology immuno-therapy
Theriva Biologics (TOVX) is an oncology company developing oncolytic viruses (viruses that kill cancer) for the treatment of solid tumors, particularly pancreatic cancer. This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism about the risks of clinical trials.
Shares shorted by the overall market
Theriva Biologics is betting on oncolytic viruses to fight cancer. This is cutting-edge, but still very early technology. This chart reflects the general pessimism. When fear reigns, investors are reluctant to fund fundamental science. They are selling off TOVX shares, fearing the company will run out of cash long before the technology proves effective.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Theriva Biologics Inc. (TOVX)
This oscillator measures hopes for a breakthrough at Theriva Biologics. The company uses oncolytic viruses—essentially "infecting" cancer tumors to destroy them. This is at the cutting edge of science. The publication of positive data showing tumor shrinkage in patients triggers an explosive "overheating" (above 70). A trial failure or safety concerns immediately send the stock plummeting (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Theriva-Biologics-Inc.-TOVX&v=1772689581079 "RSI 14 indicator chart for the company's stock Theriva Biologics Inc. (TOVX)")
RSI 14 Market Segment - Oncology immuno-therapy
Theriva Biologics is a biotech company developing oncolytic viruses—viruses programmed to infect and destroy cancer cells by stimulating an immune response. This is cutting-edge R&D. This chart reflects the overall sentiment in the immuno-oncology sector. It helps assess how overheated this entire speculative biotech segment is.
RSI 14 for the overall market
Theriva Biologics develops immunotherapy for cancer, a high-potential but high-risk sector. For companies like TOVX, market sentiment is critical. This chart shows when the overall market is euphoric, facilitating capital raising for expensive research, or panicked, with investors avoiding such risks and exiting biotech.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TOVX (Theriva Biologics Inc.)
Theriva Biologics is a biotech company developing "oncolytic viruses"—drugs that infect and destroy cancer cells (such as pancreatic cancer). This chart shows the speculative average 12-month price target from analysts, which is almost entirely dependent on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TOVX-Theriva-Biologics-Inc.&v=1772689581134 "A chart showing analyst consensus forecasts for the expected stock price. TOVX (Theriva Biologics Inc.)")
The difference between the consensus estimate and the actual stock price TOVX (Theriva Biologics Inc.)
Theriva is a biotech company that uses oncolytic viruses (Coxsackievirus) to infect and destroy cancerous tumors (such as pancreatic cancer). This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this risky but cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TOVX-Theriva-Biologics-Inc.&v=1772689581187 "A chart showing the difference between the consensus forecast and the actual stock price. TOVX (Theriva Biologics Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Theriva is an R&D biotech company developing "oncolytic viruses" (viruses that kill cancer) to treat solid tumors. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire immunotherapy sector. It shows whether experts believe in the success of "viral" cancer therapy.
Analysts' consensus forecast for the overall market share price
Theriva Biologics is a biotech company specializing in the development of "oncolytic" viruses—viruses programmed to destroy cancer cells. This chart shows the overall "risk appetite" in the market. For TOVX, which operates in a cutting-edge but high-risk field, overall market optimism (a rising chart) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Theriva Biologics Inc.
Theriva is a dual biotech. Their R&D pipeline consists of two bets: an oncolytic virus (SYN-004) that kills cancer, and a probiotic (SYN-004) that protects the gastrointestinal tract from antibiotics. This graph is a pure indicator of their R&D. It reflects their (very risky) progress in these two unrelated areas and their struggle for funding.
AKIMA Market Segment Index - Oncology immuno-therapy
Theriva Biologics is an immunotherapy company developing oncolytic viruses. These are programmed viruses designed to attack cancer cells while ignoring healthy ones. This chart compares their composite index to the sector, showing how this cutting-edge but risky strategy compares to other oncology biotechs.
The AKIM Index for the overall market
Theriva Biologics is a clinical-stage company developing enzyme therapies for cancer and rare diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how TOVX, a scientific platform, compares to overall economic trends and trials.
